

The Access To COVID-19 Tools Accelerator (ACT-A)

unicef 
for every child

VPPEF

Gian Gandhi

ACT-A/COVAX Coordinator, UNICEF Supply

15 December 2020



The Launch of ACT-Accelerator & COVAX



24 April 2020

ACT-A Launch event

Launch event of landmark collaboration to accelerate the development, production and equitable distribution of vaccines, diagnostics and therapeutics for COVID-19



04 May 2020

Coronavirus Global Response pledging event

European Commission registered €7.4 billion in pledges from donors worldwide. This includes a pledge of €1.4 billion by the Commission.



27 June 2020

EU & Global Citizens fundraising

€15.9 billion in pledges from donors worldwide. €9.8 billion from the Commission.




31 July 2020

COVAX facility launched

GAVI Board approves COVAX Advanced Market Commitment (AMC) to secure doses for 92 countries.

The ACT-Accelerator structures COVID-19 global response efforts in a collaborative framework across three partnerships



Access to COVID-19 Tools Accelerator (ACT-A)

What the ACT-A is...

- **A group** of global health actors (WHO, BMGF, CEPI, Gavi, Global Fund, UNITAID, Wellcome Trust plus UNICEF and PAHO), private sector partners, and other stakeholders
- **A free-standing collaborative task force** mobilized to promote and accelerate the development, production and equitable distribution of COVID-19 vaccines, diagnostics and therapeutics

What the ACT-A is not...

- **The ACT is not a decision-making body** – it aims at providing recommendations to its best ability, but will not undermine country/continent decision-making bodies
- **The ACT is not an extra layer** – but will act as a facilitator that uniquely brings together key stakeholders

“The newly defined partnership can achieve more than it would as a fragmented set of disconnected actors with uncoordinated decisions”

The Access to COVID-19 Tools (ACT) Accelerator Goals

VACCINES



2 billion doses by
the end of 2021

COVAX

THERAPEUTICS



245 million
therapeutics
courses for LMIC
populations by
mid-2021

Corticosteroids (e.g. Dexamethasone)
Antivirals (e.g. Remdesivir)
Monoclonal Antibodies (mAbs)

DIAGNOSTICS



500 million tests
to LMICs by
mid-2021


1. Molecular (PCR) tests
2. Antigen tests
3. Antibody tests

ACT Accelerator – Objectives


1. We commit to the shared aim of **equitable global access** to innovative tools for COVID-19 for all.
2. We commit to an unprecedented level of **partnership** – proactively engaging stakeholders, aligning and coordinating efforts, building on existing collaborations, collectively devising solutions, and grounding our partnership in transparency, and science.
3. We commit to create a **strong unified voice** to maximize impact, recognizing this is not about singular decision-making authority, but rather collective problem-solving, interconnectedness and inclusivity, where all stakeholders can connect and benefit from the expertise, knowledge and activities of this shared action-oriented platform.
4. We commit to **build on past experiences** towards achieving this objective, including ensuring that every activity we undertake is executed through the lens of equitable global access, and that the voices of the communities most affected are heard.
5. We commit to **be accountable to the world, to communities, and to one another**. We are coming together in the spirit of solidarity, and in the service of humanity, to achieve our mission and vision.

ACT-A Diagnostics Partnership– Overview

THE ACT-A DIAGNOSTICS PILLAR WILL BRING 500M TESTS TO LMICs



ACT-A Dx package to launch & scale Ag RDTs is a great win for the wider ACT-A Partnership




Diagnostics are needed for **rapid case isolation and targeting treatments**

- Enables Test/Track/Isolate... quickly and everywhere
- Essential to **preventing onward disease progression**
- Include both **Rapid Antigen Tests** and **novel Rapid Antibody tests**.

ACT-A Therapeutics Accelerator – Overview

THE ACT-A THERAPEUTICS PILLAR WILL DEVELOP AND SCALE UP EFFECTIVE THERAPEUTICS



Therapies targeted against different use cases along stages of disease progression

Use case	Prevent infection	Prevent severity	Prevent death
PrEP Pre-exposure prophylaxis	✓		
PEP Post-exposure prophylaxis	✓		
Mild	✓	✓	
Moderate		✓	
Severe & Critical			✓

Therapeutics are more than a stop-gap measure, they are **long-term solutions**


- Enable **Test & Treat** rather than Test/Track/Isolate
- Essential to **saving lives** and **preventing disease progression** across all stages of disease
- Include both **repurposed candidates (Dexamethasone)** and **novel therapies (monoclonal antibodies)**.

ACT-A requires additional \$US 35 billion deliver its full promise

Table 1: ACT-A funding ask by Pillar – as of 26 August 2020

<i>in \$US billion, rounded</i>	Total Ask	Total pledged	Financing gap
Vaccines Pillar	16	2	14
Therapeutics Pillar	7	0.3	7
Diagnostics Pillar	6	0.3	6
Health Systems Connector	9	0.1	9
TOTAL	38	3	35

Step change in financing to scale up for impact, \$ B rounded



1. Based on publicly disclosed agreements
 2. Cumulative numbers
 SOURCE: IMF Estimates; Press releases; OECD; WHO; World Bank; The Economist Intelligence Unit

- Funding is urgently needed to realize the ACT-A vision and potential.
- But it also requires countries engagement and leadership.

unicef 
for every child

Thank You

